Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Acazicolcept

Alternative Names: Acazicolcept, alpn-101, alpn101, alpn 101
Latest Update: 2025-02-07
Latest Update Note: Clinical Trial Update

Product Description

Acazicolcept is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways. The molecule is being developed for treatment of severe inflammatory diseases. (Sourced from: https://www.alpineimmunesciences.com/acazicolcept-alpn-101/)

Mechanisms of Action: CD28 Inhibitor

Novel Mechanism: Yes

Modality: Fusion Protein

Route of Administration: Intravenous,Subcutaneous

FDA Designation: Orphan Drug - Graft vs Host Disease *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: Alpine Immune Sciences

Clinical Description

Map of Global Clinical Trials for Acazicolcept

Countries in Clinic: France, Hungary, Poland, Puerto Rico, Spain, Taiwan, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Lupus Erythematosus, Systemic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
Synergy

P2

Completed

Lupus Erythematosus, Systemic

2024-07-09

2020-004047-86

P2

Active, not recruiting

Lupus Erythematosus, Systemic

None

Recent News Events

Date

Type

Title

05/09/2024

News Article

 Alpine Immune Sciences Reports First Quarter 2024 Financial Results

03/18/2024

News Article

 Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results

12/21/2023

News Article

 Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie

11/13/2023

News Article

 Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

08/01/2023

PubMed

 Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101).

03/01/2023

PubMed

 Systemic Administration of Acazicolcept, a Dual CD28 and Inducible T cell Costimulator Inhibitor, Ameliorates Experimental Autoimmune Uveitis.

01/05/2022

PubMed

 Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions